Forbes - We are strongly opposed to the company's strategy of acquiring companies or in-licensing expensive assets, especially in new therapeutic segments outside of the company's core expertise in pain management," D.E.
- Recent posts
- Prescription forgery caught by pharmacy
- Pain management...multiple doctors
- Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover ...
- Queensland tipped to feel brunt of ABC's pain
- Investor Urges Endo to Consider Sale
- Back from MD Anderson
- Research arthritis pain management
- Pain in the Neck
- Javelin Pharmaceuticals complies with Amex rules
- ER Urgent Care Centers Signs With Pro Care Health Centers
- How to choose a prescription pain relievers
- Corporate Social Responsibility
- Pain caused his hellish descent
- Pain inflicted on OxyContin
- Pain Management Support Group
- Our Mission at Pain Consultants of East Tennessee
- Lower Back Pain - What Increases Your Risk
- American Opinion
- UPDATE 2-Manulife's wealth business may feel mkt pain - CEO
- Marijuana based drug significantly reduces fibromyalgia pain